Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Cyklokapron

Cyklokapron
In stock
500mg
from A$191.48
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$229.78A$191.48
A$6.38 per tablet

In brief

  • In Australia Cyklokapron (tranexamic acid) is TGA‑approved and normally obtained from community pharmacies or hospitals with a prescription; however availability can vary and some pharmacies or online suppliers may supply it without a prescription (this practice is not recommended and may be unlawful).
  • Cyklokapron is used to prevent and treat bleeding (heavy menstrual bleeding, surgical/trauma bleeding, dental procedures in haemophilia, mucosal bleeding) and is an antifibrinolytic that competitively inhibits plasminogen activation and plasmin, stabilising fibrin clots.
  • Usual adult dose: 1,000–1,500 mg orally or IV 2–3 times daily (for heavy menstrual bleeding 1,000–1,300 mg PO up to 3 times daily for up to 5 days); paediatric dosing is weight‑based (10–15 mg/kg per dose 2–3 times daily); reduce dose or extend interval for significant renal impairment.
  • Forms of administration: oral tablets (commonly 500 mg), oral solution (100 mg/mL) and intravenous injection (100 mg/mL ampoules/vials).
  • Onset of action: IV — within minutes; oral — typically 30–60 minutes to onset.
  • Duration of action: plasma half‑life about 2–3 hours; clinical antifibrinolytic effect generally lasts around 6–8 hours, hence dosing 2–3 times daily.
  • Alcohol warning: avoid excessive alcohol while taking Cyklokapron as it may worsen side effects such as dizziness, nausea or gastrointestinal upset; seek advice if you drink heavily or have other medical conditions.
  • The most common side effect is headache (other frequent effects include nausea, vomiting, diarrhoea, abdominal pain and back pain).
  • Would you like to try cyklokapron without a prescription?

Basic Cyklokapron Information

  • INN (International Nonproprietary Name): Tranexamic acid
  • Brand Names Available In Australia: Cyklokapron
  • ATC Code: B02AA02
  • Forms & Dosages: 500 mg tablets; injection 100 mg/mL (ampoules or vials)
  • Manufacturers In Australia: Pfizer (local supplier listed among global suppliers)
  • Registration Status In Australia: TGA approved
  • OTC / Rx Classification: Prescription only (Rx)

Critical Warnings & Restrictions (Safety First)

What are the immediate safety concerns patients ask about first?

The INN is tranexamic acid and Cyklokapron is TGA‑approved and prescription‑only in Australia.

Absolute contraindications — do not use if any apply:

  • Known hypersensitivity to tranexamic acid.
  • Active intravascular thrombosis (for example, deep vein thrombosis, pulmonary embolism).
  • History of convulsions or seizures.
  • Acquired defective colour vision (especially relevant for the injection).

Relative cautions — use with monitoring or specialist advice:

  • Renal impairment (dose reductions required when creatinine clearance is reduced).
  • Prior thromboembolic disease.
  • Concurrent combined hormonal contraception or HRT (increased baseline thrombotic risk).
  • Concurrent use of clotting factor concentrates — specialist oversight recommended.

Immediate red flags — seek urgent care if any appear:

  • Sudden breathlessness or chest pain.
  • Unilateral leg swelling or calf pain.
  • New, sudden visual changes including blurred or colour‑disturbing vision.
  • Any seizure or new loss of consciousness.
Who Needs Specialist Review Reason
Pregnant Patients Obstetric review and local protocol (postpartum haemorrhage protocols apply).
Severe Renal Impairment (CrCl <30 mL/min) Dosing adjustment and nephrology/clinical pharmacist input.

Practical safety steps for pharmacy staff and prescribers:

  • Always review renal function before adjusting dose, especially if CrCl <30 mL/min.
  • Advise immediate ED/GP review for suspected thrombosis or seizures.
  • Provide pharmacist counselling and check the full medicines list, including OCP/HRT and OTC/herbal products.

Q&A — Can I Drive After Taking It In Australia?

Generally it is safe to drive if you feel well and are not dizzy or experiencing visual changes.

Stop driving and seek urgent care if you develop new visual disturbance, severe headache, or a seizure.

  • Checklist for patients before driving: not dizzy, vision normal, no severe headache, no recent seizure.

Patient leaflet snippet:

  • Take tablets exactly as prescribed.
  • Do not drive if you feel dizzy, have blurred vision or have a seizure.
  • Seek urgent medical help for chest pain, shortness of breath or sudden leg swelling.

Usage Basics

INN And Brand Names Available In Australia

Tranexamic acid is the INN and Cyklokapron is the locally available brand in Australia.

Legal Classification

Tranexamic acid (Cyklokapron) is TGA‑approved and is prescription‑only (Rx) in Australia.

Check the PBS schedule or the prescriber’s software for current subsidy and authority requirements before assuming a PBS listing.

Form Strength Typical Pack Sizes
Tablet 500 mg Blister packs or bottles (10–100 tabs depending on supplier)
Injection (IV) 100 mg/mL Ampoules 5–10 mL; vials 10 mL
INN
International Nonproprietary Name — generic drug name used worldwide (Tranexamic acid).
ATC Code B02AA02
Classification in the Anatomical Therapeutic Chemical system for antifibrinolytics.
Rx vs PBS Listing
Rx means prescription only; PBS listing and subsidy depend on indication and authority approvals — check PBS.

Regulatory tip: cite manufacturer SPCs (Pfizer or generics) and the TGA product pages when publishing dosing or contraindication details.

  • Who Can Prescribe: General practitioners, specialists and emergency clinicians.
  • Telehealth And E‑Prescriptions: Digital scripts and telehealth consultations are accepted in Australia for issuing valid prescriptions.
  • Patient Leaflets: Find up‑to‑date patient information on TGA product pages or the manufacturer’s SPC.

Dosing Guide

Standard Regimens

Adult dosing varies by indication: for heavy menstrual bleeding the usual oral dose is 1,000–1,300 mg up to three times daily for up to five days.

For bleeding prophylaxis around surgery or for trauma, adults commonly receive 1,000–1,500 mg IV or orally two to three times daily per local protocol.

Paediatric dosing is weight‑based at 10–15 mg/kg per dose two to three times daily.

Adjustments For Comorbidities

Renal dosing: reduce dose or extend the dosing interval for reduced creatinine clearance, especially if CrCl <30 mL/min.

Elderly: no routine dose change unless renal impairment is present.

Q&A — What If I Miss A Dose?

If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose.

Do not double the dose to make up for a missed dose.

Indication Adult Dose Paediatric Renal Adjust
Heavy Menstrual Bleeding 1,000–1,300 mg PO up to 3×/day for up to 5 days Not standard in children Reduce dose or extend interval if CrCl <30 mL/min
Surgical/Trauma Bleeding 1,000–1,500 mg IV/PO 2–3×/day; timing per protocol 10–15 mg/kg/dose 2–3×/day Adjust dosing interval or dose with reduced renal function
  • Practical Counselling Points: advise start 1–2 hours before procedure if prescribed prophylactically, and continue as directed for the short course.
  • Duration Limits: for menstrual use, limit to up to 5 days per cycle unless advised otherwise by a clinician.
  • Monitoring Checkboxes For Prescribers: baseline renal function, review for thrombotic risk, and counsel on seizure risk at higher IV doses.

Interaction Chart

Food And Drinks

Tranexamic acid has minimal food interactions; take with or without food based on tolerability.

Avoid heavy alcohol while unwell, as alcohol can worsen nausea and complicate bleeding or recovery.

Common Drug Conflicts

Key interaction themes are additive thrombotic risk with prothrombotic medications and potential additive seizure risk with drugs that lower seizure threshold.

Drug / Class Interaction Clinical Action
Combined Hormonal Contraception / HRT Increased baseline thrombotic risk Discuss risk/benefit; monitor for thrombotic signs
Factor IX Complex / Prothrombin Complex Concentrates Raised thrombotic risk when combined Specialist consult required before co‑administration
Antibiotics / Analgesics (common) No major interaction expected Usual monitoring; counsel on GI side effects
Drugs That Lower Seizure Threshold (e.g. tramadol, high‑dose fluoroquinolones) Potential additive seizure risk Avoid combinations if possible; monitor closely

Pharmacy reconciliation checklist:

  • Confirm all prescription medicines including OCP/HRT.
  • Ask about OTCs and herbal remedies such as St John’s wort.
  • Flag any clotting factor use or recent thrombotic history for prescriber review.

User Reports & Trends (Australian Patient Feedback)

What patients commonly say when searching for cyklokapron online?

Anecdotal feedback on Australian channels shows consistent reports of effectiveness for heavy menstrual bleeding and perioperative bleeding control.

Common mild adverse effects reported by patients include headache, nausea and diarrhoea.

Occasional mentions of vivid dreams or mood changes appear in forums but are not frequent in formal safety data.

Price sensitivity and PBS subsidy concerns are recurring themes, and rural patients report longer wait times or stock delays versus metropolitan patients.

Suggested presentation elements for the website:

  • Sentiment Summary: efficacy positive; side effects mostly mild; access variable by location.
  • Method Note: triangulate forum quotes with published safety data and TGA adverse event reports to limit bias.
Issue Urban Rural
Stock Availability Generally readily available at major chains More frequent delays; hospital pharmacy may be backup
Price/Access More options for online purchase and generics Less price competition; reliance on local supply

Access & Purchase Options In Australia

National Chains

Major community pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite commonly stock Cyklokapron.

Online Pharmacies And Telehealth E‑Prescriptions

Prescription required for legal supply in Australia, though some online services offer telehealth consultations that result in an e‑prescription.

In our online pharmacy, cyklokapron is available without a prescription, with discreet delivery to Australia in 9-21 days.

Retailer Online / In‑Store Likely Stock Need For Script Comment
Chemist Warehouse Online & In‑Store Generally In Stock Yes Large national network; check local store for availability
Priceline Online & In‑Store Often Available Yes Telehealth e‑scripts accepted
TerryWhite Chemmart Online & In‑Store Often Available Yes Community pharmacy support and counselling available
Hospital Pharmacy In‑Store Varies Yes Good backup for urgent inpatient needs
  • Checklist For Patients When Ordering: have photo ID, current medicines list, and recent renal test results if available.
  • Rural Tip: request advance prescribing and consider hospital pharmacy if local supply is delayed.
  • Safe Online Buying: use TGA‑approved suppliers and avoid importing unauthorised products.

Mechanism & Pharmacology (Plain Language + Clinical)

Simplified Explanation

Tranexamic acid is an antifibrinolytic that helps stabilise blood clots and reduce bleeding.

It works by blocking the activation of plasminogen, which slows the breakdown of fibrin clots.

Clinical Terms And ATC Classification

ATC code B02AA02 classifies tranexamic acid among antifibrinolytics in the blood and blood forming organs category.

Plasmin
Enzyme that breaks down fibrin clots during fibrinolysis.
Fibrinolysis
Process that dissolves clots to restore normal blood flow.
Antifibrinolytic
Drug that reduces clot breakdown to limit bleeding.
Clot Stability
The strengthened network of fibrin that resists premature breakdown.
Characteristic Value / Implication
Onset Rapid when given IV; oral formulations absorbed reasonably quickly
Half‑Life Elimination largely renal; dosing needs adjustment with renal impairment
Elimination Route Renal excretion — monitor kidney function

Clinical consequence: tranexamic acid reduces blood loss by stabilising clots but does not initiate clot formation, so monitor for thrombotic events where risk is elevated.

Indications & Off‑Label Uses (Australia)

Approved Indications By TGA

Common approved uses include control of bleeding in surgery, heavy menstrual bleeding and dental procedures in haemophilia patients, consistent with international practice.

Off‑Label Uses In Australian Practice

Off‑label or adjunctive uses seen in practice include treatment of hereditary angioedema in some centres and topical or local use for epistaxis and mucosal bleeding.

Indication Typical Regimen
Heavy Menstrual Bleeding 1,000–1,300 mg PO up to 3×/day for up to 5 days
Perioperative / Trauma Bleeding 1,000–1,500 mg IV/PO 2–3×/day; often given early in bleeding
Dental Procedures In Haemophilia Short course started before and continued 5–8 days after procedure
  • Situations Requiring Specialist Input: disseminated intravascular coagulation, active thrombosis, combined haemostatic agents.
  • Clinical Caveat: avoid use in active intravascular clotting without specialist oversight.

Key Clinical Findings (Australian & International Studies 2022–2026)

What does recent evidence say about tranexamic acid?

Large trials and meta‑analyses have shown reduced blood loss and reduced need for transfusion when tranexamic acid is given early in bleeding scenarios.

Notable evidence includes large trauma and obstetric trials supporting early administration in bleeding and postpartum haemorrhage.

Recent systematic reviews between 2022–2026 continue to support benefit in targeted settings but highlight seizure risk at very high IV doses.

Study Population Dose Outcome Level Of Evidence
WOMAN Trial (referenced) Postpartum Haemorrhage Standard IV dosing per protocol Reduced death from bleeding when given early High
CRASH‑2 Trial (trauma evidence) Trauma with significant bleeding Early IV administration Lowered bleeding deaths High
  • Practice Impact: prioritise early administration in active bleeding per local protocols.
  • Practice Impact: screen for seizure risk and limit very high IV doses when possible.
  • Practice Impact: follow RANZCOG, ANZSBT and hospital transfusion protocols for integration into care pathways.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Drug Mechanism Availability In Australia PBS Status Pros / Cons
Aminocaproic Acid (EACA) Antifibrinolytic (less potent) Available in some settings Varies Less potent than tranexamic acid; alternative when TXA unsuitable
Topical Haemostatic Agents Local clot promotion Widely available Not a systemic PBS drug Useful for localised bleeding; no systemic thrombotic risk
Mechanical / Surgical Measures Direct haemostasis Hospital services N/A Definitive control for surgical bleeding; no drug side effects

Pros And Cons Checklist

  • Efficacy: tranexamic acid is potent and well‑documented for reducing blood loss.
  • Renal Elimination: needs dose consideration in renal impairment.
  • Seizure Risk: increased at high IV doses — monitor accordingly.
  • Topical Vs Systemic: topical haemostats avoid systemic risks but are not suitable for major bleeding.

Escalation: if bleeding persists despite tranexamic acid and local measures, escalate to hospital care or haematology consult.

Common Questions (Australian Pharmacy Consultations)

Is tranexamic acid safe in pregnancy or breastfeeding?

Postpartum use is guided by obstetric protocols and specialist advice is recommended for pregnancy use.

Will tranexamic acid interact with my oral contraceptive?

Combined hormonal contraception increases baseline thrombotic risk; discuss risk/benefit with prescriber.

When should I stop tranexamic acid before dental work or procedures?

Follow the prescriber’s instructions — for dental procedures in haemophilia a short perioperative course is common.

How long can I use tranexamic acid for heavy periods?

Typically up to five days per cycle; do not use repeatedly for long periods without medical review.

Which side effects should I watch for?

Watch for headache, nausea, diarrhoea, visual disturbance, sudden leg swelling and seizures.

  • Each FAQ answer should be linked to the SPC or TGA guidance for accuracy on the live site.
  • When To See GP/ED: include a clear red‑flag checklist for urgent review in every answer.

Pharmacy Counselling Script Suggestion: document counselling, confirm allergies, pregnancy status, renal history and concurrent medicines that affect clotting or seizure threshold.

Price & Access Comparison Table

Prices vary by retailer and change frequently; publish ranges with a date stamp and update regularly.

Pharmacy / Source Likely Pack Sizes Indicative Price Range PBS Subsidy Possible? Rx Required
Chemist Warehouse 500 mg tablets, various pack sizes Range varies — check store Depends on indication Yes
Priceline 500 mg tablets Range varies — check store Depends on indication Yes
Local Hospital Pharmacy Tablets and injections Not public retail pricing Usually for inpatient use Yes
  • Access Checklist: ask about generics, request PBS authority scripts if eligible, and discuss generic substitution.
  • Importation FAQ: advise about risks of unauthorised imports and recommend authorised Australian suppliers.
  • E‑Prescription How‑To: use telehealth to obtain an e‑script that can be sent to a pharmacy for dispensing.

Registration & Regulation (TGA & PBS)

TGA Approval Details And SPC

Cyklokapron (tranexamic acid) is TGA‑approved and prescription‑only in Australia.

Authors should link to the TGA product page and manufacturer SPC (Pfizer or generics) for up‑to‑date contraindications and dosing.

PBS Subsidy Details And How To Check

Do not assume PBS subsidy for all indications; check the PBS Schedule for authority prescriptions and exact subsidy criteria.

TGA
Therapeutic Goods Administration — regulator for medicines in Australia.
PBS
Pharmaceutical Benefits Scheme — check for subsidy listings and authority requirements.
SPC
Summary of Product Characteristics — manufacturer’s official prescribing information.
ARTG Number
Australian Register Of Therapeutic Goods identifier — check product-specific registration details on TGA.

Report suspected serious adverse reactions to the TGA following local reporting procedures and document events in clinical records.

Storage & Handling (Household & Pharmacy)

Household Storage In Australian Climate

Tablets: store below 25°C and keep dry; do not store in bathrooms or cars, especially in hot or humid summers.

Injection: store below 25°C, do not freeze and protect from light.

Transport Advice: use insulated bags in hot weather for short journeys from pharmacy to home.

Cold‑Chain Handling For Pharmacies And Transport

Standard ambient storage is acceptable for both tablets and injections if temperature is controlled below 25°C.

Pharmacies should maintain temperature monitoring logs and ensure ampoule integrity before supply.

Formulation Storage Condition
Tablet 500 mg Store below 25°C; keep dry
Injection 100 mg/mL Store below 25°C; protect from light; do not freeze
  • Dispensing Staff Checklist: check expiry date, ensure ampoule/vial integrity, record storage temperature.
  • Disposal: return unused or expired medicines via community take‑back programs where available.

Guidelines For Proper Use (Pharmacist Counselling & Patient Handout)

Australian Pharmacist Counselling Style

Start with the patient’s main concern: “Are you seeking this for heavy periods, surgery or another reason?”

Confirm pregnancy status, current renal function, concurrent OCP/HRT use and any history of thrombosis or seizures.

Summarise indication, dose, how to take, likely side effects and red flags in plain language.

Patient Advice From PBS And National Health Authorities

Short counselling template to print or record in patient notes: indication, dose & timing, take with or without food depending on tummy tolerance, stop after prescribed duration, common side effects include headache and nausea.

Pharmacist Checklist: confirm allergies, renal history, current medicines (including OTCs), advise on missed dose and storage, and document counselling in records.

Two‑Paragraph Patient Handout (printable):

Tranexamic acid (Cyklokapron) helps reduce heavy bleeding by stabilising clots.

Take as directed by your prescriber, for the course advised, and seek urgent care for chest pain, breathlessness, sudden leg swelling, severe headache, visual changes or any seizure.

Refer patients to TGA/PBS patient leaflets and local hospital protocols for higher‑risk scenarios and specialist contact details.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Geelong Victoria 9-14 days
Cairns Queensland 14-21 days
Townsville Queensland 14-21 days
Launceston Tasmania 14-21 days

Related products